Clinical Trials Logo

Alzheimer Disease clinical trials

View clinical trials related to Alzheimer Disease.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06435078 Completed - Alzheimer Disease Clinical Trials

Developments of Novel Virtual Visual and Haptic Stimulation Systems for the Elderly

Start date: March 6, 2017
Phase: N/A
Study type: Interventional

previous studies indicated that sensory input can have positive impacts on finger force control in the elderly. Additionally, according to previous reports, apart from pharmacotherapy, nonpharmacologic interventions, such as psychosocial-environmental treatments, are emerging for the behavior and affective symptoms in AD . Moreover, enhanced finger force control and coordination lead to better hand dexterity and is believed to eventually improve life independence in the healthy elderly and the elderly with AD. Therefore, this study aims to develop novel virtual visual and haptic stimulation systems for the elderly to enhance their finger force control.

NCT ID: NCT06390098 Completed - Alzheimer Disease Clinical Trials

Positron Emission Tomography Study in Healthy Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of ASN51

Start date: August 9, 2021
Phase: Phase 1
Study type: Interventional

This is a phase 1, open-label, PET study in healthy adult subjects to determine the relationship between plasma concentration and brain target occupancy of ASN51 following a single oral dose.

NCT ID: NCT06354933 Completed - Alzheimer Disease Clinical Trials

Neurological Soft Signs in Neurodegenerative Dementias

DemeNSS
Start date: April 1, 2022
Phase:
Study type: Observational

The goal of this observational study is to investigate the prevalence of Neurological Soft Signs (NSS) in various categories of dementia patients compared to matched controls. The main questions it aims to answer are: - Does the prevalence of NSS significantly differ among patients with neurodegenerative dementias compared to controls? - Are NSS associated with neuropsychiatric alterations in dementia patients? - Do NSS correlate with cognitive screening tools? - Do NSS increase over time in patients with neurodegenerative dementias? Participants will undergo assessments including: - Evaluation of NSS using the Heidelberg scale - Neuropsychiatric assessments - Cognitive screening using the Mini-Mental State Examination (MMSE) and Frontal Assessment Battery (FAB) Researchers will compare dementia groups (Alzheimer's disease, Frontotemporal dementia, Corticobasal syndrome and Lewy body dementia) to controls to determine differences in NSS prevalence. Additionally, associations between NSS and neuropsychiatric symptoms, as well as cognitive performance, will be explored.

NCT ID: NCT06281314 Completed - Multiple Sclerosis Clinical Trials

The Efficacy of VESPA 2.0 for Cognitive Rehabilitation in Patients With Mild Cognitive Impairment

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

VESPA 2.0 is based on an integrative and ecological approach used for the treatment of cognitive dysfunction in patients with MCI or other neurodegenerative disorders.

NCT ID: NCT06275243 Completed - Alzheimer Disease Clinical Trials

Polymorphism of ApoE in Alzheimer's Disease: Genetic Study in Castile and Leon (Spain)

Start date: July 6, 2022
Phase: N/A
Study type: Interventional

The general objective of this randomized and longitudinal clinical study was to estimate the frequencies of ApoE variants both in the user population of the "Messengers of Peace" Residences and the "Associations of Relatives of Alzheimer's Patients" in Castile y Leon, since, due to its geographical location at the crossroads, it has received multiple genetic contributions from both northern Europe, the Mediterranean area and northern Africa. The main questions it aims to answer are: - What are the allelic frequencies of ApoE variants in the population of individuals with Alzheimer's disease in Castile and Leon? - Is there a correlation between the ApoE4 variant and the lipid profile in the blood of individuals with Alzheimer's disease in this region?

NCT ID: NCT06217237 Completed - Dementia Alzheimers Clinical Trials

Optimization and Harmonization of Advanced MRI Sequences

Start date: January 10, 2019
Phase:
Study type: Observational

Development of a shared multimodal MRI protocol for the definition and quantification of imaging biomarkers in AD, DLB, FDT dementias, especially white matter alterations.

NCT ID: NCT06217146 Completed - Alzheimer Disease Clinical Trials

A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.

Start date: October 12, 2022
Phase: N/A
Study type: Interventional

This double-blind, placebo-controlled study is designed to assess the effectiveness of, MediCane's balanced T3:C3 oil, a medical cannabis oil extracted from MediCane's balanced proprietary strain into GMP-grade olive oil, as an add-on therapy to standard of care (SoC), in reducing agitation and disruptive behaviors in subjects with dementia including probable AD.

NCT ID: NCT06194552 Completed - Alzheimer Disease Clinical Trials

A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07

Start date: September 6, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1, Randomized, Placebo-Controlled, Modified Parallel Design Multiple Ascending Dose Study of NTRX 07 to Assess Safety and Tolerability and Pharmacokinetics in Adult Healthy Volunteers and Subjects with MCI or Early AD. In addition, an exploratory study of the effect of a high fat meal was conducted.

NCT ID: NCT06180252 Completed - Alzheimer Disease Clinical Trials

PET Study of Acetylcholine Esterase Activity in Alzheimer's Disease

Start date: May 12, 2004
Phase:
Study type: Observational

The aim of this study is to understand regional variations in acetylcholine esterase activity in Alzheimer's disease. In this study the aim is to identify by PET the physiological values of the regional activity of acetylcholine esterase using the 11C PM4 tracer and to study by PET and 11C PM4 the brain activity of acetylcholine esterase in a group of patients with Alzheimer's disease, enrolled according to the inclusion and exclusion criteria. The PET data will be correlated with the clinical, neuropsychological and morphological data acquired by MRI and with the clinical-cognitive outcome.

NCT ID: NCT06179979 Completed - Alzheimer Disease Clinical Trials

PET Study With 11 C-PIB to Evaluate Amyloid Protein Deposits in Mild Cognitive Disorder, Alzheimer's Disease and Early Frontotemporal Degeneration.

Start date: May 17, 2008
Phase:
Study type: Observational

Preclinical and clinical data have demonstrated the ability of the 11C-PIB tracer to selectively bind accumulations of amyloid protein, a neuropathological marker characteristic of the neurodegenerative pathologies covered by this study. The validation in larger groups of patients, and the comparison between the different clinical syndromes included in the spectrum, will allow the diagnostic and prognostic potential of the tracer to be evaluated, with important consequences for the clinical management of patients. In particular, the tracer could play a central role in the clinical management of patients with neurodegenerative diseases and cognitive impairment. Numerous pharmacological trials are currently underway, worldwide, for the validation of anti-amyloid drugs. In the future we could think about early monitoring with imaging of the effectiveness of the treatment. T he FDG PET technique can be of great help in obtaining relationships between radiation damage to the brain and possibly neurological and neuropsychological deficits associates.